Clinical trials: Oral Phase
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Food Effect, Healthy
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating females. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part…
- Trial name
- NCT03150498
- Testing
- BTD-001
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Balance Therapeutics
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Periodontitis
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
This study aims to investigate the safety in using Trafermin (recombinant human basic fibroblast growth factor) with periodontal surgery.
- Trial name
- NCT01015404
- Testing
- Trafermin
- Where
- 6 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Kaken Pharmaceutical
Respiratory Syncytial Virus (RSV)
Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing…
- Trial name
- NCT02830932
- Testing
- VXA-RSV-f Tablets (high dose), VXA-RSV-f Tablets (low dose)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Vaxart
Myelodysplastic Syndrome
Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
The purpose of this study is to determine how the body absorbs decitabine when taken orally in patients with Myelodysplastic Syndrome (MDS). Safety will also be assessed for this oral dose.
- Trial name
- NCT00941109
- Testing
- decitabine
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eisai Inc.
Hepatitis B, Chronic
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
This is a multi centre, two parallel arm, randomized, open-label, Phase 2a experimental study of oral Farnesoid X Receptor (FXR) modulator EYP001a to assess its safety and anti-viral effect when administered to non-treated…
- Trial name
- NCT04365933
- Testing
- EYP001a, Entecavir, Pegylated interferon alpha2a
- Where
- 6 sites in Hong Kong, South Korea and 1 more
- Volunteers
- 20 people
- Sponsor
- Enyo Pharma
Healthy
Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers
As part of the global clinical development program for Dacomitinib, studies are planned in cancer patients in China. An assessment of Dacomitinib pharmacokinetics in Chinese subjects, as required by the Chinese Health…
- Trial name
- NCT02097433
- Testing
- Dacomitinib
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Carcinoid Syndrome
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate (LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide…
- Trial name
- NCT00853047
- Testing
- Telotristat etiprate, Octreotide LAR Depot
- Where
- 9 sites in United States
- Volunteers
- 23 people
- Sponsor
- Lexicon Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
A study of the efficacy and safety of HRS-5965 capsules compared to eculizumab for 24 weeks in patients with PNH.
- Trial name
- NCT06593938
- Testing
- HRS-5965 capsule, Eculizumab Injection
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Non-Small-Cell Lung Carcinoma
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.
- Trial name
- NCT00105092
- Testing
- Enzastaurin HCL
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Papillary Thyroid Cancer, Follicular Thyroid Cancer
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
The primary objective of this clinical study is to determine whether the inhibition of cytochrome P450 (CYP) isozyme CYP2C8 by XL184 observed in in vitro preclinical studies translates into the potential for clinically…
- Conditions
- Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer, Renal Cell Carcinoma
- Trial name
- NCT01100619
- Testing
- rosiglitazone, XL184
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Exelixis
Generalized Anxiety Disorder
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
- Trial name
- NCT06741228
- Testing
- DT120
- Where
- 34 sites in United States
- Volunteers
- 214 people
- Sponsor
- Definium Therapeutics US, Inc.
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Healthy Subjects, Pharmacokinetics of ASP3652
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
The study investigates how safe ASP3652 is and how well it is tolerated when taken as multiple doses. The study also assesses how quickly and to what extent it is absorbed and eliminated from the body.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
- Trial name
- NCT02243657
- Testing
- ASP3652
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Health Volunteer
Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RSS0343 Tablets in Healthy Subjects After Single and Multiple Oral Administration and the Effect of Food on the Pharmacokinetics of RSS0343
To evaluate the safety and tolerability of RSS0343 tablets in healthy subjects after single and multiple oral administration
- Trial name
- NCT07101965
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy
BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BT-600 when administered in single and multiple ascending doses to…
- Trial name
- NCT06275464
- Testing
- BT-600
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Biora Therapeutics, Inc.
Metrorrhagia
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
- Trial name
- NCT00307801
- Testing
- Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
- Where
- 36 sites in Australia, Czechia and 8 more
- Volunteers
- 231 people
- Sponsor
- Bayer
Healthy
Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate
The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events…
- Trial name
- NCT01568112
- Testing
- BG00012 (dimethyl fumarate), ASA
- Where
- United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Biogen
Bioavailability, Healthy Subjects
A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution
This clinical study is an open-label, randomized, 4-period, 4-treatment, crossover, single-center, single-dose bioavailability study with alternate methods of administration of crushed naloxegol tablets, 25 mg and of a naloxegol…
- Trial name
- NCT02446171
- Testing
- Naloxegol 25 mg tablet, crushed, suspended in water, given orally, Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube, Naloxegol 25 mg (10 mL oral solution)
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.